The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
Prostate cancer (PC) is one of the leading causes of cancer death in the male population. Currently, the pathogenesis of prostate cancer has been studied in sufficient detail, which makes a successful radical treatment possible in most cases. However, in about 30% of patients traditional methods (e....
Main Authors: | А. А. Gritskevich, I. G. Rusakov, Т. Р. Baitman, S. V. Mishugin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2021-06-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/6210 |
Similar Items
-
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01) -
Defective DNA repair mechanisms in prostate cancer: impact of olaparib
by: De Felice F, et al.
Published: (2017-03-01) -
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
by: Yi Ma, et al.
Published: (2018-10-01) -
POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01) -
The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)